



Contemporary management of Heart Failure in association with renal outcomes and prognosis

Heart failure and, more so, the interplay with kidney disease, have been a challenging scientific conundrum in terms of management and outcomes for the last few decades. The definition of cardiorenal syndrome (CRS) includes a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in one organ may lead to acute or chronic dysfunction in the other, and despite numerous attempts to clearly define the different phenotypes, most commonly there is a significant overlap. Despite several advances over the years in the management of the two interrelated conditions, there are several remaining unmet targets and needs.

Most recently, the evolving field of heart failure management has been excitingly expanding with the introduction of new pharmacological and interventional management approaches, including ultrafiltration. Pharmacological agents such as sodium-glucose co-transporter-2 (SGLT2) have been introduced and its use is now well-established in clinical practice. Over the last months, the advent of a new pharmacological class has been warmly welcomed by the international cardiology scientific community. With primary indication another major disease, type 2 diabetes, SGLT2 inhibitors, were unexpectedly shown to exert remarkable cardiovascular benefits, more so in association with heart failure morbidity and mortality. Most interestingly, these beneficial effects were independent of diabetes status or a glucose lowering effect but present in non-diabetic individuals, with mediating mechanisms still requiring further clarification. The same agents on the other hand, appear to exert equally impressive positive effects with regards to the progression of renal disease, which are again independent of their antidiabetic actions. This long-awaited landmark in the combined management of heart and renal disease, further highlights the underlying interrelation and the need for a unified approach to improve outcomes

Guest Editor(s):

Dr. Emmanuel Androulakis

e.androulakis@rbht.nhs.uk, em.androulakis@gmail.com

Royal Brompton & Harefield Hospital NHS Foundation Trust, London, UK



Dr. Eirini Lioudaki

eirini.lioudaki1@nhs.net, lioudaki_irini@yahoo.gr

King's College Hospital, London, UK





Message from the Editor-in-Chief

Reviews in Cardiovascular Medicine was launched in 2000 by MedReviews, LLC, in New York, NY. This journal was conceived to fill a critical gap for clinicians who were struggling with a rapidly expanding knowledge base in cardiovascular medicine with the convergence of basic science, clinical epidemiology, and therapeutic clinical trials. The founding co-editors were David P. Faxon, MD, past president of the American Heart Association, and Norman E. Lepor, MD, who is considered a luminary in interventional cardiology. The contributing editorial board grew over time and Dr. Peter A. McCullough, MD, MPH ascended from contributing, to associate, to co-editor of the Journal. In 2018, the Journal took its next big step under the leadership of Dr. McCullough as editor-in-chief to become a truly international publication. Its offices moved to IMR Press in Hong Kong, and the editorial board was made more inclusive and representative of the world-wide contributors in academic cardiology. Additionally, the journal brought on expertise in translational medicine to help face the future of molecular medicine and its role in cardiovascular disease. Today Reviews in Cardiovascular Medicine is considered a top tier journal in cardiology with timely and comprehensive reviews covering all aspects of cardiovascular medicine including atherosclerosis, myocardial disease, arrhythmias, and valvular heart disease. The scope of papers ranges from population science, applied basic investigation, in-vitro diagnostics, and evidence-based strategy and therapeutic trials involving both pharmacologic intervention and interventional devices. The highly integrative style of the Journal anchored with evidence tables and instructive figures has garnered many citations over the years and many guidelines documents have relied upon works published in Reviews in Cardiovascular Medicine. Supplement and focus issues have been very popular among the readership and often are viewed as the most up-to-date compilations of new knowledge in cardiology and related specialities. The future is bright for academic cardiovascular medicine and Reviews in Cardiovascular Medicine is well positioned along side the clinician-investigator in the years to come as a trusted source of critical information and analysis.

Editor-in-chief:



Dr. Peter A. McCullough, MD, MPH

peteramccullough@gmail.com

Baylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, United States



Submission Deadline: 30 September 2021

Submission: <https://www.editorialmanager.com/joins/Default.aspx>

Contact us: RCMeditorial@imrpress.org